Press Release

  • The Desperate Need For Medical Isotopes

    The Desperate Need For Medical Isotopes

    The Desperate Need For Medical Isotopes

    Los Angeles, CA. March 18, 2019 – With preparations underway for manufacturing the MIFTEC Z-pinch (ZEBRA) Fusion Medical Isotope Generators, US Nuclear Corp. (OTCBB: UCLE) is one step closer to ending the dire worldwide shortage of medical isotopes.  The federal government is so desperate to find a domestic, stable supply of medical isotopes that they recently awarded over $60 million in funding to 8 projects/companies working on solutions for this demand.  Of these 8 companies, only 3 have timelines to supply medical isotopes in the near future, and of those 3, Magneto-Inertial Fusion Technologies, Inc (MIFTI, parent company to MIFTEC) has the most promising solution.  MIFTEC’s patented fusion-powered medical isotope generator can not only solve the medical isotope shortage, but the revolutionary process also offers numerous advantages to current production methods, including:

    • MIFTEC’s process is fueled by a simple isotope of hydrogen from a renewable source: seawater.
      Current production methods of medical isotopes are fission-based nuclear reactors or accelerators that require either highly enriched or low enriched uranium (HEU/LEU) to operate. These methods are costly, multi-step processes that result in nuclear waste byproducts that must be safely contained and stored for hundreds of years while being protected from theft by terrorists.
    • Due to the eco-friendly, fusion-based technology, the capital and operational costs are a fraction of that for fission or accelerator technology.  Additionally, medical isotope production costs are up to 50% less than all other current manufacturing processes.
    • The device is designed to fit into most hospitals, nuclear medicine clinics, and laboratories.  It is ideal for local, domestic production, and results in a major reduction in transportation and import costs.  Local production also solves the timeline issues of Mo-99’s 66-hour half-life.
    • No production limit problem.  Current methods to build a nuclear reactor or accelerator are time-consuming and expensive, and once finally built, these facilities have a maximum production limit.  There is currently around a $5 billion shortfall in medical isotope production. US Nuclear can build MIFTEC’s medical isotope generators in a fraction of the time and cost, with the production line continuing until demand has been filled.

    Safe Harbor Act

    This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

    Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at https://www.usnuclearcorp.com

    CONTACT:

    US Nuclear Corp. (UCLE)
    Robert I. Goldstein, President, CEO, and Chairman
    Rachel Boulds, Chief Financial Officer
    (818) 883 7043
    Email: info@usnuclearcorp.com

    Yahoo Finance

  • US Nuclear/FlyCam Sells Fleet of DroneRads to Saudi Arabia Civil Defense

    US Nuclear/Flycam Sells Fleet of Drone-Rads to Saudi Arabia Civil Defense

    US Nuclear/FlyCam Sells Fleet of DroneRads to Saudi Arabia Civil Defense

    Los Angeles, CA. January 23, 2019 – US Nuclear Corp. (OTCBB: UCLE) is proud to announce that it has sold a fleet of DroneRAD systems to the Saudi Arabia Civil Defense.  This order brings US Nuclear’s current order backlog to the $2,000,000 range. The DroneRAD is aerial radiation and chemical detection system which utilizes the revolutionary Neo and Zoe drones offered by FlyCAM UAV. These aerial platforms are rugged, robust, weatherproof, and can withstand high winds up to 35 knots (40 mph) and temperature extremes (-10°C / 13°F) without compromising flight capabilities. The DroneRADwill be used by the Saudi Arabia Civil Defense for national security purposes.

    The DroneRAD sensor system is designed for both radiation and chemical detection and is highly sensitive and durable even in hostile environmental conditions. Several different sensor packages are available that range from conducting neutron or gamma surveys, to measuring airborne particulates and chemical contaminants.

    (more…)

  • US Nuclear Reports 3rd Quarter 2018 Results – 35.6% Increase in Revenue

    US Nuclear Reports 3rd Quarter 2018 Results – 35.6% Increase in Revenue

    Los Angeles, CA. November 20, 2018 – US Nuclear Corp. (OTCBB: UCLE)

    • Sales for the three months ended September 30, 2018, were $1,145,480, an increase of 35.6% for the same period in 2017
    • Gross profit was $512,096, an increase of 34% for the same period in 2017
    • During the three months ended September 30, 2018, the company entered into an agreement with MIFTEC and paid $1,084,000 for certain manufacturing and supply rights as discussed below
    • Net loss from operations ($1,414,715) due to stock-based compensation and acquisition of manufacturing and supply rights offset by an increase in gross profits due to higher sales (more…)
  • US Nuclear Announces Revenue Is Up 80% Over Past 2 Years

    US Nuclear Announces Revenue Is Up 80% Over Past 2 Years

    Los Angeles, CA. October 29, 2018 – US Nuclear Corp. (OTCBB: UCLE) recently reported strong worldwide revenue growth of 80% from 2016 based on the 2018 YTD sales rate. One main factor driving the growth in revenue is a targeted sales effort of US Nuclear’s unique signature products. These products include drinking water monitors, nuclear power plant air and stack monitors, USN/FlyCAM UAV DroneRADs, personnel and vehicle monitors, and tritium monitors.

    US Nuclear Corp’s annual sales revenue for 2016 was $2,097,157 which rose to $3,070,646 for 2017.  The current 2018 YTD revenue for the first 3 quarters is $2,706,785, signifying a 2018 YTD sales rate of $3,600,000/year, an increase of 80% from 2016. Additionally, US Nuclear currently has a comfortable order backlog of $1,393,167.

    Robert Goldstein, CEO of US Nuclear Corp, commented, “Looking forward, we are very optimistic.  We have focused our sales efforts on our signature product lines, which have been gaining momentum among our sales representatives and customers as they migrate to US Nuclear’s brand due to our superior reliability, performance, and innovative functionality and capabilities not found anywhere else.”

    (more…)

  • US Nuclear Corp with Drone Partner Flycam UAV Performs Dronerad Flight Demonstration for Urban Shield Event

    US Nuclear Corp with Drone Partner Flycam UAV Performs Dronerad Flight Demonstration for Urban Shield Event

    Los Angeles, CA. September 13, 2018 – US Nuclear Corp (OTCBB: UCLE) recently attended and participated in the Urban Shield event from September 7-10, 2018 in the Bay Area.  Urban Shield is a disaster training exercise involving local, national, and international first responder agencies, including the national guard, police and fire departments, search & rescue, homeland security, FBI, FEMA, DOE, and many more.  The main goal of Urban Shield is to evaluate the preparedness and the capabilities of first responders in response to high-level threats in high-density areas and finding ways in which to improve.

    US Nuclear Corp participated in an emergency service scenario wherein a car containing radioactive material had been blown up.  Radioactive sources were placed in/near the blown-up vehicle to create a live scenario. US Nuclear Corp and their drone partner FlyCam UAV flew FlyCam UAV’s NEO octocopter equipped with US Nuclear Corp’s radiation sensor search tool, the DroneRAD-ST, over the incident area to map the radioactive hotspots before emergency responders moved in to mitigate the situation.

    US Nuclear Corp. Partner Achieves Historic Milestone for Nuclear Fusion

    FlyCam UAV’s NEO, a heavy-lifting, all-weather octocopter mounted with US Nuclear Corp’s Gamma Search Tool sensor is designed to detect radioactive Gamma emitting hotspots on the ground and log and transmit the GPS tagged data back in real-time.  The mission was successfully completed and the DroneRAD-ST mounted on FlyCam UAV’s NEO demonstrated its ability to measure and pinpoint the Gamma sources and overlay all the data on Google Maps. This provided first responders a real-time visual of the radioactive zones and where the concentration was the highest.  It was widely agreed by all the emergency service personnel present that the NEO mounted DroneRAD-ST is an essential tool that every first-responder service should have for emergencies involving radiation exposure.

    US Nuclear Corp’s unique DroneRAD-ST was the only radiation and chemical detecting UAV mounted radiation sensor present at Urban Shield. As emergency services continue to improve, there will be a greater emphasis on acquiring the special tools needed to effectively address certain emergencies, especially in high-density areas.  This includes the DroneRAD-ST detector system mounted on FlyCam UAV’s drone platforms for quick surveying and mapping radiation-related emergencies thus mitigating first responder and public exposure to potentially harmful radiation.

    Safe Harbor Act

    This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

    Investors may find additional information by visiting US Nuclear Corp. and the SEC website.

    CONTACT:

    US Nuclear Corp. (OTCBB: UCLE)
    Robert I. Goldstein, President, CEO, and Chairman
    Ph: (818) 883 7043
    Email: info@usnuclearcorp.com
    https://www.usnuclearcorp.com

  • US Nuclear Corp. Partner Achieves Historic Milestone for Nuclear Fusion

    US Nuclear Corp. Partner Achieves Historic Milestone for Nuclear Fusion

    Good news for Cancer and Heart Patients

    Los Angeles, CA, Aug. 29, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — US Nuclear Corp. (UCLE):
    US Nuclear Corporation’s partner recently achieved a significant milestone in nuclear fusion by exceeding 1010 neutrons per pulse with MIFTEC Fusion power technology designed for use in US Nuclear Isotope generator. This historic, high-level neutron flux is far above what any other fusion company has ever achieved, and is a large step towards the final goal of producing medical isotopes in a localized medical setting.

    The method that US Nuclear Corp. and MIFTEC Laboratories Inc. are working to develop is simple, safe, and cost-effective. It uses an isotope of hydrogen as fuel, which is derived from seawater and is simple, safe, and cost-effective compared to the current method of using highly enriched or low enriched uranium (HEU/LEU) that results in dangerous, long-term radioactive byproducts.

    With US Nuclear being designated as the exclusive manufacturer of the MIFTEC isotope generators. And, with the radiopharmaceutical market currently a $10B USD worldwide industry, US Nuclear Corp. and MIFTEC Laboratories, Inc. plans to be a major market participant upon reaching final testing and implementation.

    (more…)

  • Lucas Heights Reactor Shutdown Highlights Need for US Nuclear Corp. Technology

    Lucas Heights Reactor Shutdown Highlights Need for US Nuclear Corp. Technology

    Los Angeles, CA, July 16, 2018 (GLOBE NEWSWIRE) — It was recently announced that a nuclear reactor in Australia, the Open Pool Australian Lightwater (OPAL), had temporarily shut down shipments and suspended production of a valuable medical isotope, molybdenum-99 (Mo-99).  Mo-99 decays into technetium-99m (Tc-99m), which is used by hospitals for critical nuclear medicine diagnostic procedures. The suspension was caused by mechanical problems at the site, and severely highlights the need for an alternative, stable supply of medical isotopes.

    US Nuclear (OTCMKTS:UCLE) Has Become Investor’s Preferred Choice

    OPAL is a key part of the global supply of Mo-99, which is handled by a fragile network of isotope suppliers.  Fewer than a dozen nuclear reactors supply the entire world.  Unfortunately, these isotopes cannot be stockpiled due to the relatively short half-lives; Mo-99 has a half-life of 66 hours, while Tc-99m has a half-life of only 6 hours. There is already an enormous shortage of medical isotopes, and any production problems with current suppliers drastically exacerbate the situation.

    A partnership between US Nuclear Corp. and MIFTEC aims to solve the global isotope shortage by manufacturing and selling medical isotope generators that can produce these isotopes at 50% of the current cost. MIFTEC is designing the medical isotope generator based off their parent company’s z-pinch fusion technique, which produces the high flux needed for isotope generation.  US Nuclear Corp., having over 70 years of manufacturing experience in the nuclear industry, was appointed the exclusive manufacturer for these isotope generators for N. America and Asia.

    CONTACT:

    US Nuclear Corp. (UCLE)
    Robert I. Goldstein, President, CEO, and Chairman
    Rachel Boulds, Chief Financial Officer
    (818) 883 7043
    Email: info@usnuclearcorp.com

  • MIFTEC and US Nuclear Join Race to Fill $7 Billion/Year Shortage of Medical Isotopes

    MIFTEC and US Nuclear Join Race to Fill $7 Billion/Year Shortage of Medical Isotopes

    Los Angeles, CA. June 5, 2018—US Nuclear Corp (OTCBB: UCLE) and MIFTEC recently signed a definitive agreement which formally appoints US Nuclear as the exclusive manufacturer of MIFTEC’s revolutionary medical isotope generators for North America and Asia, and makes US Nuclear a sales representative for all MIFTEC products. This definitive agreement replaces the Letter of Intent signed back in December 2017. MIFTEC’s parent company, MIFTI Nuclear Fusion, is a leader in developing fusion power and has shown that their staged Z-pinch fusion technique produces high neutron flux which can be used to produce medical isotopes at a fraction of the cost of current methods.

    US Nuclear (OTCMKTS:UCLE) Has Become Investor’s Preferred Choice

    There are two main uses for medical isotopes: diagnosis and treatment. Diagnostic procedures using radioisotopes are now routine, and can be used to examine blood flow to the brain, functioning of the liver, lungs, heart, or kidneys—the advantage over other techniques being that you can image both bone and soft tissue, and assess what is happening physiologically. The most prominent treatment application is for cancer, using radiation to weaken or destroy targeted cancer cells.

    (more…)

  • US Nuclear Appointed To SelL zNOSE® High-Speed GC Chemical Sniffers

    US Nuclear Appointed To SelL zNOSE® High-speed GC Chemical Sniffers

    Los Angeles, CA. May 21, 2018 – US Nuclear Corp. (OTCBB: UCLE) and Electronic Sensor Technology Inc. have signed a worldwide sales representative and resale agreement giving US Nuclear non-exclusive rights to sell the revolutionary, high-speed zNose®chemical sniffers.

    The zNose®chemical sniffers recently featured in CBS Television’s CSI Miami, use advanced Surface Acoustic Wave sensors and ultra-fast gas chromatography to separate and analyze vapor samples in near real-time. The patented technology detects all compounds within an odor to provide a complete chemical profile, and the software includes an expandable library of over 700 chemicals and odor signatures, allowing the zNose to recognize virtually any target odor.

    (more…)

  • US Nuclear Corp. Announces 2017 Annual Financial Results

    US Nuclear Corp. Announces 2017 Annual Financial Results

    Los Angeles, CA. April 19, 2018 – US Nuclear Corp. (OTCBB: UCLE)

    2017 Annual Highlights

    • Total sales revenue of $3,070,646, an increase of 46.4% compared to the previous year
    • Gross profit for 2017 was $1,344,913, an increase of 72% compared to the previous year
    • Profitable net income of $10,130
    • The gross margin increased to 43.8% as compared to 36.9% the previous year
    • General and administrative expense increased by 17.2% due to costs in developing and marketing new products, specifically the Drone-RAD UAV line

    “We’re thrilled to report on a successful year in 2017 with total sales revenue growth of 46.4%,” commented Robert Goldstein, CEO of US Nuclear Corp. “The increase in revenue was due to robust sales of our signature air monitors to nuclear power plants in addition to the popular demand of our tritium air monitors, which included a large contract with the USAF.  Gross margin is increasing as we finish R&D on several new products that are being brought to the market.  Overall, 2017 was a very strong year for us, but we are not at our full manufacturing capacity yet and will focus our efforts in 2018 to increase the volume even further by capturing more of the global tritium monitor market, focusing on business from the new power plant and fusion development, and introducing our new products mentioned above.”

    (more…)